• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Perspective Therapeutics Inc.

    4/16/26 4:10:52 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care
    Get the next $CATX alert in real time by email
    DEFA14A 1 defa14a_-_notice_card_20.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

     

    Preliminary Proxy Statement

     

     

     

    ☐

     

    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

     

    ☐

     

    Definitive Proxy Statement

     

     

     

    ☒

     

    Definitive Additional Materials

     

     

     

    ☐

     

    Soliciting Material under to § 240.14a-12

     

    PERSPECTIVE THERAPEUTICS, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

     

    No fee required.

     

     

     

    ☐

     

    Fee paid previously with preliminary materials.

     

     

     

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

    img113525813_0.jpg

    Your Vote Counts! PERSPECTIVE THERAPEUTICS, INC. 2026 Annual Meeting Vote by May 26, 2026 11:59 PM Eastern Time PERSPECTIVE THERAPEUTICS, INC. 2401 ELLIOTT AVENUE, SUITE 320 SEATTLE, WA 98121 V92322-P47541 You invested in PERSPECTIVE THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 27, 2026. Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 13, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote in Person at the Meeting* May 27, 2026 9:00 a.m. Central Time The Sheraton Grand Chicago Riverwalk 301 E North Water Street Chicago, IL 60611 *To attend in person, you must pre‑register with your 16-digit control number at www.proxyvote.com by 5:00 p.m. Pacific Time on May 13, 2026. Please check the meeting materials for any additional special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.


     

    img113525813_1.jpg

    Vote at www.ProxyVote.comTHIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review all of the important information contained in the proxy materials before voting. Voting Items 1. Election of Directors Nominees: 01) Lori A. Woods 02) Heidi Henson 03) Robert Froman Williamson, III 04) Frank Morich, M.D., Ph.D. 05) Johan (Thijs) Spoor 06) Maya Martinez-Davis 2. To ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. 3. To approve, on a non-binding advisory basis, the frequency of advisory stockholder votes on the compensation of the Company’s named executive officers. Board Recommends For All For 1Year Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     


    Get the next $CATX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CATX

    DatePrice TargetRatingAnalyst
    2/19/2026$16.00Overweight
    Piper Sandler
    11/24/2025$12.00Buy
    Truist
    10/10/2025$14.00Buy
    BTIG Research
    3/13/2025$10.00Buy
    H.C. Wainwright
    3/7/2025$15.00Sector Outperform
    Scotiabank
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    10/24/2024$20.00Buy
    UBS
    10/1/2024$25.00Outperform
    Wedbush
    More analyst ratings

    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Perspective Therapeutics with a new price target

    Piper Sandler initiated coverage of Perspective Therapeutics with a rating of Overweight and set a new price target of $16.00

    2/19/26 7:52:02 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Truist resumed coverage on Perspective Therapeutics with a new price target

    Truist resumed coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $12.00

    11/24/25 9:17:24 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    BTIG Research initiated coverage on Perspective Therapeutics with a new price target

    BTIG Research initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $14.00

    10/10/25 8:39:44 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Perspective Therapeutics to Participate in Upcoming Investor Conferences

    SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: 25th Annual Needham Virtual Healthcare Conference – Presentation & Fireside ChatDate: Tuesday, April 14, 2026Time: 9:30-10:10 a.m. ET Location: Virtual Piper Sandler Spring Biopharma Symposium – 1x1s onlyDate: Thursday, April 16, 2026Location: Boston, MA About Perspective Therapeutics, Inc.

    4/2/26 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

    SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026. PresenterAbstract TitlePresentation DetailsThorvardur Halfdanarson, Mayo Clini

    3/17/26 4:45:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

    Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoingData across all dose levels in the VMT-α-NET program provide development optionality and support the build-out of a robust clinical evidence package for submission for presentation to more medical conferences and regulatory engagement in 2026Clinical updates for all three clinical programs are expected to be submitted f

    3/16/26 4:07:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 6:44:41 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Perspective Therapeutics Inc.

    DEFA14A - Perspective Therapeutics, Inc. (0000728387) (Filer)

    4/16/26 4:10:52 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Perspective Therapeutics Inc.

    DEF 14A - Perspective Therapeutics, Inc. (0000728387) (Filer)

    4/16/26 4:10:05 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    4/1/26 4:16:31 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Martinez Maria E

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    3/4/26 4:38:30 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Morich Frank

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    3/4/26 4:38:07 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Williamson Robert F Iii

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    3/4/26 4:37:44 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Leadership Updates

    Live Leadership Updates

    View All

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

    SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin

    9/3/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $CATX
    Financials

    Live finance-specific insights

    View All

    Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

    Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on studyInitial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3, expected during 2026Perspective will hold a conference call on Monday, October 20, 2025 at 8:30 am ET SEATTLE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering adv

    10/20/25 4:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

     Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatmentFour of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject

    5/30/25 5:21:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

      Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh

    1/24/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 4:05:13 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/7/24 9:24:55 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care